Unknown

Dataset Information

0

Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis-design, rationale, and methodology of the METEOR-China study.


ABSTRACT: BACKGROUND:The beneficial effect of statins on atherosclerosis and cardiovascular outcomes has been well established. The Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin (METEOR) global study demonstrated that a 2-year orally administered treatment with rosuvastatin 40?mg daily significantly slowed the progression of carotid intima-media thickness (CIMT) compared to placebo. The current METEOR-China study is designed to evaluate the effect of rosuvastatin 20?mg daily versus placebo on the progression of atherosclerosis measured by CIMT in asymptomatic Chinese subjects. METHODS:This is a phase 3, randomised, double-blind, placebo-controlled, multicentre parallel-group study. Asymptomatic Chinese subjects with a 10-year ischaemic cardiovascular disease (ICVD) risk

SUBMITTER: Wang Y 

PROVIDER: S-EPMC7656706 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis-design, rationale, and methodology of the METEOR-China study.

Wang Yilong Y   Wang Anxin A   Li Hongwei H   Li Zhanquan Z   Hu Bo B   Li Xiaogang X   Zheng Huaguang H   Fu Lu L   Hu Hongtao H   Nie Zhiyu Z   Qin Yulin Y   Zhao Bilian B   Wei Di D   Karlson Björn W BW   Bots Michiel L ML   Chen Yundai Y   Wang Yongjun Y  

Trials 20201111 1


<h4>Background</h4>The beneficial effect of statins on atherosclerosis and cardiovascular outcomes has been well established. The Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin (METEOR) global study demonstrated that a 2-year orally administered treatment with rosuvastatin 40 mg daily significantly slowed the progression of carotid intima-media thickness (CIMT) compared to placebo. The current METEOR-China study is designed to evaluate the effect of rosuvastatin 20 mg  ...[more]

Similar Datasets

| S-EPMC4430520 | biostudies-literature
| S-EPMC3146552 | biostudies-literature
| S-EPMC6723244 | biostudies-literature
| S-EPMC5089877 | biostudies-other
| S-EPMC4361257 | biostudies-literature
| S-EPMC4934849 | biostudies-other
| S-EPMC9267611 | biostudies-literature
| S-EPMC10310726 | biostudies-literature
| S-EPMC11371917 | biostudies-literature
| S-EPMC5663464 | biostudies-literature